Moderna’s Great Immunological Blunder
Many have asked me how Moderna, a dedicated mRNA company, could make such a bad product out of the gate as their first market entry? Much of the answer relates to a development blunder made by Moderna scientists dating back many years.
Because mRNA rapid design and implementation is so enthralling, companies like Moderna began to imagine any disease that could be modulated by harnessing human cells to produce a protein of interest. In their 2018 Securities and Exchange Commission 10-K filing there is a figure that caught my attention. Moving right to left one can see the thought process of young molecular biologists with dreams of treating broad range of diseases.
Source: Substack
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.